Vancouver-based Cannabix Technologies Inc. has launched a series of new product videos showcasing its Marijuana Breath Test (MBT) system. The announcement, made on December 19, 2025, comes at a pivotal moment as the United States moves to reclassify cannabis, highlighting a growing demand for tools to detect recent use and enhance public safety.
A Timely Solution for a Changing Landscape
The company's new marketing materials highlight the features of its Marijuana Breath Test (MBT) solution. This technology is designed to detect recent cannabis use through a non-invasive breath sample. Cannabix positions the device as a critical tool for improving workplace safety and providing law enforcement with a modern method for roadside screening.
Cannabix directly links the product's relevance to a major policy shift in the United States. The U.S. Administration's executive order to fast-track the reclassification of marijuana to Schedule III under the Controlled Substances Act is seen as a catalyst for increased cannabis liberalization. This change, the company argues, underscores the urgent need for reliable detection methods like the MBT to manage the implications of wider use.
Technology and Strategic Partnership
The core of the MBT system involves proprietary hardware: a Handheld Breath Collection Unit (BCU) and Breath Cartridge (BC) technologies. These components are engineered to collect and preserve breath samples for subsequent analysis. The company utilizes gold-standard liquid chromatography-mass spectrometry (LC-MS) methods to ensure accurate detection of THC, the primary psychoactive compound in cannabis.
A key element of Cannabix's commercialization strategy is its strategic partnership with Omega Laboratories Inc., a forensic drug testing leader with over 25 years of experience. Omega holds multiple federal and international certifications, and this collaboration is focused on advancing the MBT system for customers in both the U.S. and Canada.
Broader Corporate Focus
Cannabix Technologies Inc., publicly traded on the Canadian Securities Exchange (CSE: BLO), develops breath testing technologies for both marijuana and alcohol. The company's portfolio also includes the BreathLogix autonomous alcohol screening device, aimed at organizations seeking to improve safety protocols. The launch of the new MBT videos represents a significant step in the company's marketing and stakeholder communication efforts.
The company cautions that this news release contains forward-looking statements subject to various risks and uncertainties. These include the development and commercialization of products, regulatory approvals, and market conditions. Cannabix notes it is not currently selling the MBT and there is no guarantee it will do so in the future.
The new product videos are available for viewing on the company's official website at cannabixtechnologies.com.
